1Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007 [J].CA Cancer J Clin, 2007, 57 (1) : 43-66.
2Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thy- roid nodules and differentiated thyroid cancer [ J ]. Thyroid, 2009, 19 (11): 1167-1214.
3Davies L, Ouellette M, Hunter M, et al. The increasing incidence of small thyroid cancers: where are the cases coming from? [ J]. Laryngoscope, 2010, 120(12) :2446-2451.
4Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma : benefits and limits of radioiodine therapy [ J ]. J Clin Endocrinol Metab, 2006, 91 (8) :2892-2899.
5Ahmed M, Barbachano Y, Riddell A, et al. Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase Ⅱ study in a UK based population[J]. Eur J Endocrinol, 2011, 165(2) :315-322.
6Ravaud A, de la Fouchardiere C, Courbon F, et al. Sunitinib in patients with refractory advanced thyroid cancer: the THYSU phase Ⅱ trial[J]. J Clin Oncol, 2008, 26 (suppl) : A6058.
7Robinson BG, Paz-Ares L, Krebs A, et al. Vandetanib (100 mg)in patients with locally advanced or metastatic hereditary medullary thy- roid cancer[J]. J Clin Endocrinol Metab, 2010, 95(6) :2664-2671.
